Table 4

Overview of efficacy on secondary outcome variables: adjusted means (95% CI) for intention-to-treat sample using the last observation carried forward method

Parameter Placebo Venlafaxine ER
37.5 mg 75 mg 150 mg
HRSA, Hamilton Rating Scale for Anxiety; HAD, Hospital Anxiety and Depression scale; CGI-S, Clinical Global Impression of Severity; BSA, Brief Scale for Anxiety; SAS-SR, Self-Rated Social Adjustment Scale.
1.Significantly different from placebo (P ≤ 0.05) on the pairwise comparison; two-way ANCOVA.
2.Significantly different from 37.5 mg of venlafaxine ER (P ≤ 0.05) on the pairwise comparison; two-way ANCOVA.
3.Significantly different from 75 mg of venlafaxine ER (P ≤ 0.05) on the pairwise comparison; two-way ANCOVA.
HRSA somatic anxiety factor, baseline adjusted mean 11.8
Week 8 7.0 (6.3-7.8) 6.2 (5.5-6.9) 5.6 (4.9-6.4)1 5.4 (4.6-6.1)1
Week 24 6.4 (5.6-7.2) 5.5 (4.8-6.3) 4.7 (3.9-5.5)1 4.5 (3.7-5.3)1
HRSA anxious mood item, baseline adjusted mean 2.8
Week 8 1.8 (1.6-2.0) 1.5 (1.3-1.7)1 1.4 (1.2-1.6)1 1.2 (1.1-1.4)1,2
Week 24 1.8 (1.6-2.0) 1.3 (1.1-1.5)1 1.2 (1.0-1.4)1 1.0 (0.8-1.2)1,2
HAD depression sub-scale, baseline adjusted mean 8.2
Week 8 7.0 (6.3-7.6) 6.1 (5.5-6.7)1 5.1 (4.4-5.7)1,2 4.8 (4.1-5.4)1,2
Week 24 6.5 (5.7-7.2) 5.6 (4.9-6.3) 5.0 (4.3-5.8)1 3.8 (3.1-4.6)1,2,3
CGI—S, baseline adjusted mean 4.5
Week 8 3.3 (3.1-3.5) 3.1 (2.8-3.3) 2.8 (2.6-3.0)1 2.6 (2.4-2.8)1,2
Week 24 3.1 (2.8-3.4) 2.7 (2.4-2.9)1 2.5 (2.3-2.8)1 2.2 (1.9-2.4)1,2
BSA total score, baseline adjusted mean 26.0
Week 8 17.7 (16.2-19.2) 15.3 (13.8-16.7)1 13.4 (11.9-14.9)1 13.0 (11.5-14.5)1,2
Week 24 16.9 (15.3-18.6) 13.8 (12.2-15.4)1 11.9 (10.2-13.5)1 10.7 (9.1-12.4)1,2
SAS—SR overall, baseline adjusted mean 2.2
Week 8 2.0 (1.9-2.1)1,2 2.0 (1.9-2.0) 1.9 (1.8-1.9)1,2 1.8 (1.7-1.9)1,2
Week 24 1.9 (1.9-2.0) 1.9 (1.8-2.0) 1.8 (1.7-1.9)1 1.7 (1.7-1.8)1,2